Add like
Add dislike
Add to saved papers

Success of probing for congenital nasolacrimal duct obstruction in children under 10 years of age.

OBJECTIVE: To determine the success of probing for congenital nasolacrimal duct obstruction in children aged under 10 years.

DESIGN: A retrospective study.

MATERIAL AND METHOD: The medical records of all children aged under 10 years diagnosed with congenital nasolacrimal duct obstruction between 1997 and 2007 who underwent probing and irrigation under general anesthesia were reviewed. Successful probing was defined as absence of tearing and eye discharge in the affected eye at one month or more after treatment. Data obtained included age at first visit, gender laterality of the eyes, history of previous probing, age at probing time, number of probing, and treatment outcomes. Patients were categorized into four groups according to age at treatment (0-1 year, 1-2 years, 2-3 years and 3-10 years).

RESULTS: Forty-four patients were seen during the study period, 19 males and 25females, with 29 right eyes and 30 left eyes undergoing treatments of 29 unilateral probing and 15 bilateral probing. The age at probing ranged from 10 months to 9.6 years (mean +/- SD, 2.51 +/- 1.82 years). Successful probing were identified in 47 out of 59 eyes (80%, 95% CI = 67 to 89%). Most successful eyes required only one probing and only two eyes needed a second probing. The success rates were 80% (8/10 eyes) in patients 0-1 year of age, 86% (18/21 eyes) in patients 1-2 years of age, 75% (12/16 eyes) in patients 2-3 years of age, and 75% (9/12 eyes) in patients 3-10 years of age.

CONCLUSION: The success rate of probing for treatment of congenital nasolacrimal duct obstruction varies, depending on the age of the child at treatment. It was higher in children under 2 years than in older children.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app